Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Pharmacol Exp Ther
2011 Oct 01;3391:125-31. doi: 10.1124/jpet.111.185306.
Show Gene links
Show Anatomy links
Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor.
Lummis SC
,
Thompson AJ
,
Bencherif M
,
Lester HA
.
???displayArticle.abstract???
Varenicline, a widely used and successful smoking cessation agent, acts as a partial agonist at nicotinic acetylcholine receptors. Here, we explore the effects of varenicline at human and mouse 5-Hydroxytryptamine(3) (5-HT(3)) receptors. Application of varenicline to human 5-HT(3) receptors expressed in Xenopus laevis oocytes reveal it is almost a full agonist (R(max) = 80%) with an EC(50) (5.9 μM) 3-fold higher than 5-HT. At mouse 5-HT(3) receptors varenicline is a partial agonist (R(max) = 35%) with an EC(50) (18 μM) 20-fold higher than 5-HT. Displacement of the competitive 5-HT(3) receptor antagonist [(3)H]granisetron reveals similar IC(50) values for varenicline at mouse and human receptors expressed in human embryonic kidney 293 cells, although studies in these cells using a membrane potential-sensitive dye show that again varenicline is a 4- or 35-fold less potent agonist than 5-HT in human and mouse receptors, respectively. Thus the data suggest that the efficacy, but not the affinity, of varenicline is greater at human 5-HT(3) receptors compared with mouse. Docking studies provide a possible explanation for this difference, because they suggest distinct orientations of the ligand in the mouse versus human 5-HT(3) agonist binding sites. Additional binding selectivity studies in a broad panel of recombinant receptors and enzymes confirmed an interaction with 5-HT(3) receptors but revealed no additional interactions of varenicline. Therefore, activation of human 5-HT(3) receptors may be responsible for some of the side effects that preclude use of higher doses during varenicline treatment.
Aubin,
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.
2008, Pubmed
Aubin,
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial.
2008,
Pubmed
Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed
Coe,
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
2005,
Pubmed
,
Xenbase
Davies,
The 5-HT3B subunit is a major determinant of serotonin-receptor function.
1999,
Pubmed
,
Xenbase
Dubin,
The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit.
1999,
Pubmed
,
Xenbase
Faessel,
Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
2009,
Pubmed
Faessel,
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
2006,
Pubmed
Fiebich,
Expression of 5-HT3A receptors in cells of the immune system.
2004,
Pubmed
Lester,
Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.
2009,
Pubmed
Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase
Lowe,
A novel series of [3.2.1] azabicyclic biaryl ethers as alpha3beta4 and alpha6/4beta4 nicotinic receptor agonists.
2010,
Pubmed
Lummis,
A cation-pi binding interaction with a tyrosine in the binding site of the GABAC receptor.
2005,
Pubmed
Mihalak,
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
2006,
Pubmed
,
Xenbase
Miller,
Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion.
1992,
Pubmed
Miwa,
Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses.
2011,
Pubmed
Miyake,
Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species.
1995,
Pubmed
Nayak,
Nicotinic receptors co-localize with 5-HT(3) serotonin receptors on striatal nerve terminals.
2000,
Pubmed
Niesler,
Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E.
2003,
Pubmed
Price,
The role of tyrosine residues in the extracellular domain of the 5-hydroxytryptamine3 receptor.
2004,
Pubmed
,
Xenbase
Price,
FlexStation examination of 5-HT3 receptor function using Ca2+ - and membrane potential-sensitive dyes: advantages and potential problems.
2005,
Pubmed
Reeves,
The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review).
2002,
Pubmed
Rollema,
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
2010,
Pubmed
,
Xenbase
Rollema,
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
2007,
Pubmed
Thompson,
The structural basis of function in Cys-loop receptors.
2010,
Pubmed
Thompson,
Antimalarial drugs inhibit human 5-HT(3) and GABA(A) but not GABA(C) receptors.
2008,
Pubmed
,
Xenbase
Thompson,
An efficient and information-rich biochemical method design for fragment library screening on ion channels.
2010,
Pubmed
Thompson,
The 5-HT3 receptor as a therapeutic target.
2007,
Pubmed
Tzvetkov,
Tissue-specific alternative promoters of the serotonin receptor gene HTR3B in human brain and intestine.
2007,
Pubmed
